Correction for Antman et al., Circulation 105 (14) 1642-1649.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Related Collections Fibrinolysis Heparin Other anticoagulants Acute myocardial infarction

(Circulation. 2002;105:2799.)
© 2002 American Heart Association, Inc.

Correction

In the article, "Enoxaparin as Adjunctive Antithrombin Therapy for ST-Elevation Myocardial Infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial" by Antman et al that appeared online on March 4, 2002, as a Rapid Track (Circulation. 2002;105:r27–r34) and in the April 9, 2002, issue of the journal (Circulation. 2002;105:1642–1649), an error appeared in Figure 2.

The inset portion in the top right corner of Figure 2 shows the following values for the 30-day mortality, recurrent infarction, and composite death/MI rates for the unfractionated heparin (UFH) and enoxaparin (ENOX) groups, respectively: 3.1%, 7.5%, and 10.7% versus 3.1%, 1.9%, and 5.0%. The P value for comparison of the recurrent infarction rate was shown as 0.002 and that for the composite death/MI rate as 0.012.

The correct numbers are as follows: For the UFH group, 30-day mortality rate was 3.1%, recurrent infarction rate was 8.2%, and the composite rate was 11.3%. For the ENOX group, 30-day mortality rate was 3.1%, recurrent infarction rate was 1.8%, and the composite rate was 4.9%. The P value for comparison of the recurrent infarction rates was 0.002 and that for comparison of the composite death/MI rate was 0.01.